腾盛博药(02137) - 2025 - 年度业绩

Announcement Background and Purpose Brii Biosciences Limited issues a supplemental announcement to provide additional details on the use of net proceeds from its global offering in the 2024 annual report, specifically regarding unutilized funds carried forward to January 1, 2024 - This announcement supplements the 2024 annual report, focusing on the use of net proceeds from the global offering[2] - It highlights the specific amount of unutilized net proceeds as of December 31, 2023, carried forward to January 1, 2024[2] Details on Use of Net Proceeds from Global Offering This section details the original and revised uses of the company's global offering net proceeds, utilized amounts as of December 31, 2024, and unutilized funds carried forward from December 31, 2023, to January 1, 2024, covering various R&D projects and working capital - As of December 31, 2024, a total of HKD 25.256 million of net proceeds from the global offering has been utilized (HKD 9.941 million from Group 1 allocation and HKD 15.315 million from Group 2 allocation)[3][4] - As of December 31, 2024, HKD 1.760 million remains unutilized, primarily allocated to Group 1 R&D projects and working capital[3] Unutilized Net Proceeds as of December 31, 2023, Carried Forward to January 1, 2024 As of December 31, 2023, HKD 14.666 million of the company's global offering net proceeds remained unutilized and was carried forward to January 1, 2024, primarily for R&D projects like BRII-179, BRII-877, and working capital Unutilized Net Proceeds as of December 31, 2023, Carried Forward to January 1, 2024 (Million HKD) | Project | Original Proposed Use (Million HKD) | Revised Proposed Use (Million HKD) | Unutilized Net Proceeds (Million HKD) | Percentage of Original Total Net Proceeds (%) | | :------------- | :------------------------------- | :------------------------------- | :------------------------------- | :------------------------- | | BRII-179 | 11.959 | 11.959 | 7.848 | 46% | | BRII-732 | 1.307 | 1.307 | 1.400 | 5% | | BRII-835 | 0.261 | 0.261 | 1.307 | 5% | | BRII-877 | 14.666 | 14.666 | 5.141 | 56% | | BRII-753 | 1.400 | 1.400 | 1.400 | 6% | | Other R&D Projects | 1.517 | 1.517 | 1.517 | 32% | | Working Capital and Other General Corporate Purposes | 8.373 | 8.373 | 11.959 | 1% | | Total | 26.138 | 26.138 | 14.666 | 100% | Overview of Net Proceeds Utilization as of December 31, 2024 As of December 31, 2024, a total of HKD 25.256 million from the global offering net proceeds has been utilized (HKD 9.941 million from Group 1 and HKD 15.315 million from Group 2), with HKD 1.760 million remaining unutilized, primarily in Group 1 R&D projects and working capital Utilization of Group 1 Allocated Funds Of the HKD 26.138 million net proceeds from the global offering allocated to Group 1, HKD 9.941 million was utilized as of December 31, 2024, primarily for R&D projects like BRII-179, BRII-877, and working capital, with HKD 1.760 million remaining unutilized Utilization of Group 1 Allocated Funds as of December 31, 2024 (Million HKD) | Project/Purpose | Original Proposed Use (Million HKD) | Revised Proposed Use (Million HKD) | Funds Utilized (Million HKD) | Unutilized Net Proceeds as of 2024-12-31 (Million HKD) | | :--------------------- | :------------------------------- | :------------------------------- | :------------------------------- | :----------------------------------------------------------------- | | BRII-179 | 11.959 | 11.959 | 6.818 | 1.555 | | BRII-732 | 1.307 | 1.307 | 1.517 | 1.307 | | BRII-835 | 0.261 | 0.261 | 0.243 | 0.261 | | BRII-877 | 14.666 | 14.666 | 3.123 | 1.825 | | BRII-753 | 1.400 | 1.400 | 1.825 | 0.053 | | Other R&D Projects | 1.517 | 1.517 | 4.948 | 3.380 | | Working Capital and Other General Corporate Purposes | 8.373 | 8.373 | 0.296 | 0.261 | | Total | 26.138 | 26.138 | 9.941 | 1.760 | Utilization of Group 2 Allocated Funds The HKD 15.315 million net proceeds from the global offering allocated to Group 2 were fully utilized as of December 31, 2024, primarily for R&D projects like BRII-297, BRII-636, and working capital, with no unutilized balance Utilization of Group 2 Allocated Funds as of December 31, 2024 (Million HKD) | Project/Purpose | Original Proposed Use (Million HKD) | Revised Proposed Use (Million HKD) | Funds Utilized (Million HKD) | Unutilized Net Proceeds as of 2024-12-31 (Million HKD) | | :--------------------- | :------------------------------- | :------------------------------- | :------------------------------- | :----------------------------------------------------------------- | | BRII-297 | 0.675 | 0.675 | 0.675 | 0 | | BRII-636 | 0.590 | 0.590 | 0.590 | 0 | | BRII-672 | 0.085 | 0.085 | 0.085 | 0 | | BRII-296 | 2.746 | 2.746 | 2.746 | 0 | | BRII-693 | 3.920 | 3.920 | 3.920 | 0 | | Other R&D Projects | 2.614 | 2.614 | 2.614 | 0 | | Working Capital and Other General Corporate Purposes | 26.138 | 26.138 | 26.138 | 0 | | Total | 15.315 | 15.315 | 15.315 | 0 | Other Information and Board Statement The additional information disclosed in this supplemental announcement does not affect other content in the 2024 annual report, with all other information remaining unchanged, and includes details on the company's board members - The additional information in this supplemental announcement does not affect other information in the 2024 annual report[5] - Board members include Executive Directors Dr Zhi Hong and Dr Li Ankang, along with several Independent Non-executive Directors[6]